Arovella Therapeutics Ltd has released a press release.
Voluntary Suspension
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Trading Halt
- Arovella $20m Placement - fully funded to complete Phase 1
- Arovella receives R&D tax rebate of $3.0 million
- Positive pre-IND feedback from FDA for ALA-101
- Zolpimist Update
Later from Arovella Therapeutics
- Arovella $15m Placement to fund Phase 1
- Prospectus
- Reinstatement to Official Quotation
- Research Agreement with University of North Carolina
- S&P DJI Announces March 2025 Quarterly Rebalance
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics